APIMEDS PHARMACEUTICALS US I (APUS) Stock Fundamental Analysis

USA • NYSE Arca • NYSEARCA:APUS • US03771D1028

1.85 USD
-0.08 (-4.15%)
Last: Jan 30, 2026, 08:04 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to APUS. APUS was compared to 525 industry peers in the Biotechnology industry. APUS has a great financial health rating, but its profitability evaluates not so good. APUS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • APUS had negative earnings in the past year.
APUS Yearly Net Income VS EBIT VS OCF VS FCFAPUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -200K -400K -600K -800K -1M

1.2 Ratios

  • APUS's Return On Assets of -13.18% is amongst the best of the industry. APUS outperforms 81.52% of its industry peers.
  • Looking at the Return On Equity, with a value of -14.27%, APUS belongs to the top of the industry, outperforming 86.29% of the companies in the same industry.
Industry RankSector Rank
ROA -13.18%
ROE -14.27%
ROIC N/A
ROA(3y)-7193.47%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
APUS Yearly ROA, ROE, ROICAPUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -2K -4K -6K -8K -10K

1.3 Margins

  • APUS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APUS Yearly Profit, Operating, Gross MarginsAPUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, APUS has about the same amount of shares outstanding.
  • Compared to 1 year ago, APUS has a worse debt to assets ratio.
APUS Yearly Shares OutstandingAPUS Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2M 4M 6M 8M 10M
APUS Yearly Total Debt VS Total AssetsAPUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 200K 400K 600K

2.2 Solvency

  • APUS has an Altman-Z score of 16.96. This indicates that APUS is financially healthy and has little risk of bankruptcy at the moment.
  • APUS's Altman-Z score of 16.96 is amongst the best of the industry. APUS outperforms 88.00% of its industry peers.
  • There is no outstanding debt for APUS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 16.96
ROIC/WACCN/A
WACCN/A
APUS Yearly LT Debt VS Equity VS FCFAPUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 -500K -1M

2.3 Liquidity

  • A Current Ratio of 12.79 indicates that APUS has no problem at all paying its short term obligations.
  • The Current ratio of APUS (12.79) is better than 87.81% of its industry peers.
  • A Quick Ratio of 12.79 indicates that APUS has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 12.79, APUS belongs to the top of the industry, outperforming 87.81% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.79
Quick Ratio 12.79
APUS Yearly Current Assets VS Current LiabilitesAPUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 200K 400K 600K 800K 1M

More info and screens

0

3. Growth

3.1 Past

  • APUS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -78.72%.
EPS 1Y (TTM)-78.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • APUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APUS Price Earnings VS Forward Price EarningsAPUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APUS Per share dataAPUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • APUS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

APIMEDS PHARMACEUTICALS US I / APUS FAQ

What is the ChartMill fundamental rating of APIMEDS PHARMACEUTICALS US I (APUS) stock?

ChartMill assigns a fundamental rating of 3 / 10 to APUS.


What is the valuation status of APIMEDS PHARMACEUTICALS US I (APUS) stock?

ChartMill assigns a valuation rating of 0 / 10 to APIMEDS PHARMACEUTICALS US I (APUS). This can be considered as Overvalued.


What is the profitability of APUS stock?

APIMEDS PHARMACEUTICALS US I (APUS) has a profitability rating of 2 / 10.


How financially healthy is APIMEDS PHARMACEUTICALS US I?

The financial health rating of APIMEDS PHARMACEUTICALS US I (APUS) is 8 / 10.